Figure 1From: Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial Study design. Schema representing the four-period cross-over investigation, composed of 2 periods with ESAs administration scheduled at 4 weeks intervals (Q4W) and 2 periods with ESAs administration scheduled at 2 weeks intervals (Q2W).Back to article page